Nchroma Bio received clinical trial authorization in Hong Kong to start a first‑in‑human Phase I/II study of CRMA‑1001 for chronic hepatitis B virus infection, with dosing expected early next year. The regulatory certificate enables the company to begin dosing and collect initial safety, tolerability and pharmacokinetic data. CRMA‑1001 represents Nchroma’s lead antiviral candidate against HBV; the trial will enroll healthy volunteers and/or patients per protocol and aims to establish a clinical profile to support further development and potential global filings. The authorization positions Nchroma to advance translational studies and seek partnerships for broader development.